[Liver steatogenic power of high doses of rifampicin in rats].
The possible induction of fatty liver by Rifampicin has been investigated by oral administration of two different doses (200 and 400 mg/kg/24 h) of this antibiotic for a period of 8 days to male and female Rats. The results obtained are more constant and more coherent in male than in female. It is the 400 mg/kg/24 h dose which is more effective, leading to an increase of lipids, triglycerides and cholesterol in the liver and a decrease of serum triglycerides. A dose-effect relationship may exist. These preliminary data lead us to believe that Rifampicin may inhibit the synthesis of the protein moiety of lipoproteins, such as alpha-Amanitin, which is also a RNA-polymerase inhibitor.
D000818:Animals; D002784:Cholesterol / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005234:Fatty Liver / Q000139:chemically induced*; D005260:Female; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000096:biosynthesis; D008297:Male; D051381:Rats; D012293:Rifampin / Q000008:administration & dosage; D012737:Sex Factors; D014280:Triglycerides / Q000378:metabolism
D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol; D012293:Rifampin
Premières données relatives au pouvoir stéatogène hépatique de doses élevées de rifampicine chez le rat.